SCHEMBL4573757

SCHEMBL4573757

O=C(O)COc1ccc(C2=NNC(=O)CC2)cc1Cl

nearest known ligand 0.54

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
PDE3B Q13370 7/20 0.54
PDE3A Q14432 7/20 0.54
PDE4B Q07343 4/20 0.54
PDE4A P27815 3/20 0.54
PDE4C Q08493 3/20 0.54
PDE4D Q08499 3/20 0.54
TDP1 Q9NUW8 2/20 0.51
TSHR P16473 1/20 0.47
SMN1; SMN2 Q16637 1/20 0.47
MAPT P10636 2/20 0.46
LMNA P02545 1/20 0.46
NPY1R P25929 1/20 0.46
NPY2R P49146 1/20 0.46
CYP2C19 P33261 1/20 0.46
KMT2A Q03164 1/20 0.44
GPR119 Q8TDV5 1/20 0.41
HRH3 Q9Y5N1 1/20 0.41
PTGDR2 Q9Y5Y4 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7327893 0.88 PDE3B (0.52) PDE3BPDE3APDE4BPDE4APDE4C
SCHEMBL14046117 0.87 PDE3B (0.56) PDE3BPDE3APDE4BPDE4APDE4C
SCHEMBL10474304 0.86 PDE3B (0.50) PDE3BPDE3APDE4BPDE4APDE4C
SCHEMBL4573518 0.85 PDE3B (0.52) PDE3BPDE3APDE4BPDE4APDE4C
SCHEMBL14606586 0.85 PDE3B (0.51) PDE3BPDE3APDE4BPDE4APDE4C
SCHEMBL8191155 0.84 PDE3B (0.61) PDE3BPDE3APDE4BPDE4APDE4C
SCHEMBL4890576 0.83 PDE3B (0.54) PDE3BPDE3APDE4BPDE4APDE4C
SCHEMBL7337123 0.82 PDE3B (0.46) PDE3BPDE3APDE4BPDE4APDE4C
SCHEMBL10475276 0.82 HPGD (0.60) PDE3BPDE3APDE4BPDE4APDE4C
SCHEMBL7328514 0.82 PDE3B (0.48) PDE3BPDE3APDE4BPDE4APDE4C

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080262226-A1 METHODS OF MAKING COMPOUNDS HAVING A BETA-ADRENERGIC INHIBITOR AND A LINKER AND METHODS OF MAKING COMPOUNDS HAVING A BETA-ADRENERGIC INHIBITOR, A LINKER AND A PHOSPHODIESTERASE INHIBITOR ARTESIAN THERAPEUTICS, INC. (CA) 2008-10-23 US disclosed
US-20080262226-A1 METHODS OF MAKING COMPOUNDS HAVING A BETA-ADRENERGIC INHIBITOR AND A LINKER AND METHODS OF MAKING COMPOUNDS HAVING A BETA-ADRENERGIC INHIBITOR, A LINKER AND A PHOSPHODIESTERASE INHIBITOR ARTESIAN THERAPEUTICS, INC. (CA) 2008-10-23 US disclosed
US-20080262226-A1 METHODS OF MAKING COMPOUNDS HAVING A BETA-ADRENERGIC INHIBITOR AND A LINKER AND METHODS OF MAKING COMPOUNDS HAVING A BETA-ADRENERGIC INHIBITOR, A LINKER AND A PHOSPHODIESTERASE INHIBITOR ARTESIAN THERAPEUTICS, INC. (CA) 2008-10-23 US disclosed
US-20080255134-A1 Cardiotonic Compounds With Inhibitory Activity Against Beta-Adrenergic Receptors And Phosphodiesterase ARTESIAN THERAPEUTICS, INC. (US) 2008-10-16 US disclosed
US-20080255134-A1 Cardiotonic Compounds With Inhibitory Activity Against Beta-Adrenergic Receptors And Phosphodiesterase ARTESIAN THERAPEUTICS, INC. (US) 2008-10-16 US disclosed
US-20080255134-A1 Cardiotonic Compounds With Inhibitory Activity Against Beta-Adrenergic Receptors And Phosphodiesterase ARTESIAN THERAPEUTICS, INC. (US) 2008-10-16 US disclosed
WO-2008058198-A1 METHODS OF MAKING COMPOUNDS HAVING A BETA-ADRENERGIC INHIBITOR AND A LINKER AND METHODS OF MAKING COMPOUNDS HAVING A BETA-ADRENERGIC INHIBITOR, A LINKER AND A PHOSPHODIESTERASE INHIBITOR CARDIOME PHARMA CORP. (CA) 2008-05-15 WO disclosed
WO-2008058198-A1 METHODS OF MAKING COMPOUNDS HAVING A BETA-ADRENERGIC INHIBITOR AND A LINKER AND METHODS OF MAKING COMPOUNDS HAVING A BETA-ADRENERGIC INHIBITOR, A LINKER AND A PHOSPHODIESTERASE INHIBITOR CARDIOME PHARMA CORP. (CA) 2008-05-15 WO disclosed
US-20080090827-A1 Compounds With Mixed Pde-Inhibitory and Beta-Adrenergic Antagonist or Partial Agonist Activity For Treatment of Heart Failure ARTESIAN THERAPEUTICS, INC. (US) 2008-04-17 US disclosed
US-20080090827-A1 Compounds With Mixed Pde-Inhibitory and Beta-Adrenergic Antagonist or Partial Agonist Activity For Treatment of Heart Failure ARTESIAN THERAPEUTICS, INC. (US) 2008-04-17 US disclosed
WO-2004033444-A1 DIHYDROPYRIDINE COMPOUNDS HAVING SIMULTANEOUS ABILITY TO BLOCK L-TYPE CALCIUM CHANNELS AND TO INHIBIT PHOSPHODIESTERASE TYPE 3 ACTIVITY ARTESIAN THERAPEUTICS, INC. (US) 2004-04-22 WO disclosed
WO-2004033444-A1 DIHYDROPYRIDINE COMPOUNDS HAVING SIMULTANEOUS ABILITY TO BLOCK L-TYPE CALCIUM CHANNELS AND TO INHIBIT PHOSPHODIESTERASE TYPE 3 ACTIVITY ARTESIAN THERAPEUTICS, INC. (US) 2004-04-22 WO disclosed
US-5258519-A FOR TREATMENT OF HYPERTENSION AND CARDIAC CONDITIONS GLAXO INC. (US) 1993-11-02 US disclosed
US-5204463-A Substituted methoxyphenyl-4,5 dihydro-3(2H)-pridazinones having cardiotonic and beta blocking activities GLAXO INC. (US) 1993-04-20 US disclosed
US-5100892-A Hypotensive agents, congestive heart failure GLAXO INC. (US) 1992-03-31 US disclosed
US-5096904-A Congestive heart failure GLAXO INC. (US) 1992-03-17 US disclosed
US-5053338-A Hydrolysis of ester to obtain an optically enriched mixture of a phenol enantiomer GLAXO INC. (US) 1991-10-01 US disclosed
US-4914093-A CARDIOVASCULAR DISORDERS SANKYO COMPANY LIMITED (JP) 1990-04-03 US disclosed
EP-0330242-A1 Pyridazinone derivatives, their preparation and use Sankyo Company Limited (JP) 1989-08-30 EP disclosed
EP-0178189-A2 Pyridazinone derivatives, their preparation and use SANKYO COMPANY LIMITED (JP) 1986-04-16 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080090827-A1 Compounds With Mixed Pde-Inhibitory and Beta-Adrenergic Antagonist or Partial Agonist Activity For Treatment of Heart Failure ADRB3, PDE3A, PDE3B PDE3B 3/4885PDE3A 2/4885PDE4B 8/4885
US-20080262226-A1 METHODS OF MAKING COMPOUNDS HAVING A BETA-ADRENERGIC INHIBITOR AND A LINKER AND METHODS OF MAKING COMPOUNDS HAVING A BETA-ADRENERGIC INHIBITOR, A LINKER AND A PHOSPHODIESTERASE INHIBITOR ADRB2, ADRB3, ADRB1 PDE3B 6/4885PDE3A 4/4885PDE4B 54/4885
US-20080255134-A1 Cardiotonic Compounds With Inhibitory Activity Against Beta-Adrenergic Receptors And Phosphodiesterase ADRB3, PDE3A, ADRB1 PDE3B 4/4885PDE3A 2/4885PDE4B 8/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.